Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications

Yuen, M. -F.; Yuan, H. -J.; Wong, D. K. -H.; Yuen, J. C. -H.; Wong, W. -M.; Chan, A. O. -O.; Wong, B. C. -Y.; Lai, K. -C.; Lai, C. -L.
November 2005
Gut;Nov2005, Vol. 54 Issue 11, p1610
Academic Journal
Background: Identifying risk factors for the development of complications of chronic hepatitis B (CHB) is important for selling up treatment criteria. Aim: To determine risk factors For the development of complications in Asian CHB patients. Patients and methods: A total of 3233 Chinese CHB patients (mean follow up 46.8 months) were monitored for liver biochemistry, viral serology, hepatitis B virus (HBY) DNA levels, acute exacerbation, hepatitis B e antigen (HBeAg) seroconversion, and development of cirrhotic complications and hepatocellular carcinoma. Results: Median age for HBeAg seroconversion and development of complications was 35 years and 57.2 years, respectively. Patients with alanine aminotransferase (ALT) levels of 0.5-1 times the upper limit of normal (ULN) and 1-2x ULN had an increased risk for the development of complications compared with patients with ALT levels <0.5 x ULN (p<0.0001 for both). HBeAg/antibody to hepatitis B e antigen status, and number of episodes, duration, and peak ALT levels of acute exacerbations were not associated with an increased risk of complications. In patients with complications, 43.6% had HBV DNA levels less than 1.42 × 105 copies/ml. Male sex, stigmata of chronic liver disease, old age, low albumin, and high a fetoprotein levels on presentation were independently associated with increased cumulative risk of complications. Male sex, presence of hepatitis symptoms, old age, low albumin level, and presence of complications on presentation were independently associated with shorter survival. Conclusion: Prolonged low level viraemia causing insidious and continual liver damage, as reflected by ALT levels of 0.5-2x ULN, is the most likely pathway for the development of complications in Asian CHB patients.


Related Articles

  • Factors associated with spontaneous HBsAg clearance in chronic hepatitis B patients followed at a university hospital. Ferreira, Sandro C.; Chachá, Silvana G. F.; Souza, Fernanda F.; Teixeira, Andreza C.; Santana, Rodrigo C.; Villanova, Márcia G.; Zucoloto, Sérgio; Ramalho, Leandra N.; Perdoná, Gleici S. C.; Passos, Afonso D. C.; Martinelli, Ana L. C. // Annals of Hepatology: Official Journal of the Mexican Associatio;Nov/Dec2014, Vol. 13 Issue 6, p762 

    Introduction. Few studies have evaluated the factors involved in the spontaneous HBsAg seroclearance in patients with chronic hepatitis B (HBV) followed up on a long-term basis from areas with a low prevalence of HBV infection. We aimed to determine the rate of spontaneous HBsAg seroclearance...

  • Pseudoknots: RNA Structures with Diverse Functions. Staple, David W.; Butcher, Samuel E. // PLoS Biology;Jun2005, Vol. 3 Issue 6, p0956 

    The article reports that RNA molecules fulfill a diverse set of biological functions within cells, from the transfer of genetic information from DNA to protein, to enzymatic catalysis. Reflecting this range of roles, simple linear strings of RNA--made up of uracil, guanine, cytosine, and...

  • Entecavir approved for treating chronic hepatitis B. Lamb, Ed // Pharmacy Today;Jun2005, Vol. 11 Issue 6, p13 

    The article reports that Bristol-Myers Squibb's entecavir was approved for treating chronic hepatitis B virus (HBV) infection on March 30 and became available to pharmacies under the brand name Baraclude within 2 weeks. The guanosine nucleoside analog works in three ways to prevent the...

  • The Natural History and Treatment of Chronic Hepatitis B: A Critical Evaluation of Standard Treatment Criteria and End Points. Ching-Lung Lai; Man-Fung Yuen // Annals of Internal Medicine;7/3/2007, Vol. 147 Issue 1, p58 

    The definite indications for the treatment of chronic hepatitis B are serum hepatitis B virus (HBV) DNA levels greater than 105 copies/mL and alanine aminotransferase (ALT) levels more than 2 times the upper limit of normal. If cirrhosis is present, an HBV DNA level greater than 105 copies/mL is...

  • Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Bonino, F.; Marcellin, P.; Lau, G. K. K.; Hadziyannis, S.; Jin, R.; Piratvisuth, T.; Germanidis, G.; Yurdaydin, C.; Diago, M.; Gurel, S.; Lai, M.-Y.; Brunetto, M. R.; Farci, P.; Popescu, M.; McCloud, P. // Gut;May2007, Vol. 56 Issue 5, p699 

    Objective: In a trial of patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B, 24 week post-treatment biochemical and virological response rates with peginterferon α-2a with or without lamivudine were significantly higher than with lamivudine alone. The effect of...

  • Hepatitis B Virus Genotype D Isolates Circulating in Chapecó, Southern Brazil, Originate from Italy. Gusatti, Carolina Souza; Costi, Cintia; Halon, Maria Laura; Grandi, Tarciana; Medeiros, Arlete Ferrari Rech; Silva, Cláudia Maria Dornelles; Gomes, Selma Andrade; Silva, Marcia Susana Nunes; Niel, Christian; Rossetti, Maria Lucia Rosa // PLoS ONE;8/14/2015, Vol. 10 Issue 8, p1 

    Hepatitis B virus genotype A1 (HBV/A1), of African origin, is the most prevalent genotype in Brazil, while HBV/F predominates in the other South American countries. However, HBV/D is the most common in the three states of southern Brazil, where ‘islands’ of elevated prevalence, as...

  • Hepatitis B reactivation after withdrawal of preemptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Hui, C. -K.; Cheung, W. W. W.; Au, W. Y.; Lie, A. K. W.; Zhang, H. -Y.; Yueng, Y. -H.; Wong, B. C. Y.; Leung, N.; Kwong, Y. -L.; Liang, R.; Lau, G. K. K. // Gut;Nov2005, Vol. 54 Issue 11, p1597 

    Background: The hepatic outcome of hepatitis B surface antigen (HBsAg) positive patients undergoing chemotherapy after withdrawal of pre-emptive lamivudine is unknown. Aims: To examine the occurrence of hepatitis B virus (HBV) reactivation after withdrawal of pre-emptive lamivudine. Methods:...

  • Hepatocellular Carcinoma.  // Clinical Infectious Diseases;5/1/2006, Vol. 42 Issue 9, following pe78 

    The article reports that the risk of development of cirrhosis and of hepatocellular carcinoma increases in patients with chronic hepatitis B virus (HBV) infection. The risk for the development of hepatocellular carcinoma begins to increase when HBV DNA level starts increasing alarmingly. It also...

  • Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT. Viganò, M.; Vener, C.; Lampertico, P.; Annaloro, C.; Pichoud, C.; Zoulim, F.; Facchetti, F.; Poli, F.; Scalamogna, M.; Deliliers, G. Lambertenghi; Colombo, M. // Bone Marrow Transplantation;Jan2011, Vol. 46 Issue 1, p125 

    Allogeneic hematopoietic SCT (HSCT) increases the risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen (HBsAg) carriers but the incidence, risk factors and course of HBV reactivation after HSCT in HBsAg-negative/anti-hepatitis B core antigen (anti-HBc)-positive recipients...


Read the Article


Sign out of this library

Other Topics